Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Fernö, Mårten LU ; Nordenskjöld, Bo and Rydén, Lisa LU
(2009)
In European Journal of Cancer
45.
p.2496-2502
- Abstract
- BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a... (More)
- BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p=0.02). In subgroup analysis the risk reduction was most pronounced in patients <40 years of age (HR 0.09, p=0.02). A risk reduction was also seen in women 40-49 years of age or >/=50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. CONCLUSION: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women <40 years of age. The effect of tamoxifen was not significantly dependent on time. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1434183
- author
- Alkner, Sara
LU
; Bendahl, Pär-Ola
LU
; Fernö, Mårten
LU
; Nordenskjöld, Bo
and Rydén, Lisa
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Cancer
- volume
- 45
- pages
- 2496 - 2502
- publisher
- Elsevier
- external identifiers
-
- wos:000270645100017
- pmid:19535242
- scopus:69249133380
- ISSN
- 1879-0852
- DOI
- 10.1016/j.ejca.2009.05.022
- language
- English
- LU publication?
- yes
- id
- f714f0f5-ceb9-46b9-bfb0-5352547206b3 (old id 1434183)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19535242?dopt=Abstract
- date added to LUP
- 2016-04-04 07:32:24
- date last changed
- 2022-01-29 02:16:40
@article{f714f0f5-ceb9-46b9-bfb0-5352547206b3,
abstract = {{BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p=0.02). In subgroup analysis the risk reduction was most pronounced in patients <40 years of age (HR 0.09, p=0.02). A risk reduction was also seen in women 40-49 years of age or >/=50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. CONCLUSION: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women <40 years of age. The effect of tamoxifen was not significantly dependent on time.}},
author = {{Alkner, Sara and Bendahl, Pär-Ola and Fernö, Mårten and Nordenskjöld, Bo and Rydén, Lisa}},
issn = {{1879-0852}},
language = {{eng}},
pages = {{2496--2502}},
publisher = {{Elsevier}},
series = {{European Journal of Cancer}},
title = {{Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.}},
url = {{http://dx.doi.org/10.1016/j.ejca.2009.05.022}},
doi = {{10.1016/j.ejca.2009.05.022}},
volume = {{45}},
year = {{2009}},
}